Bart Barlogie, MD;Raymond Alexanian, MD;Sundar Jagannath, MD JAMA.1992;268(20):2946-2951. doi:10.1001/jama.1992.03490200198025 FullText Abstract PLASMA cell dyscrasias refer to a spectrum of disorders characterized by the monoclonal proliferation of lymphoplasmacytic cells in the bone marrow and, ...
Plasma cell disorders encompass a number of diagnostic entities, with the most common being multiple myeloma. These disorders typically affect multiple organ systems, and patients can present with a spectrum of symptoms. Evaluation of these disorders requires a comprehensive set of laboratory and ...
The invention relates to novel biological markers for plasma cell disorders, such as multiple myeloma, and in particular to the use of microRNAs as diagnostic and prognostic markers
PLASMA cell dyscrasias refer to a spectrum of disorders characterized by the monoclonal proliferation of lymphoplasmacytic cells in the bone marrow and, sometimes, tissue deposition of monoclonal immunoglobulins or their components (Table 21-1). The disorders include multiple myeloma (MM) and Waldenstr...
86 C H A P T E R PLASMA CELL NEOPLASMS Nikhil C. Munshi and Sundar Jagannath Multiple myeloma (MM) is a malignancy involving terminally dif- ferentiated plasma cells. It includes a spectrum of plasma cell disorders ranging from monoclonal gammopathy of unknown significance (MGUS), a ...
Plasma cell dyscrasiasare a heterogeneous group of disorders caused by the monoclonal proliferation of lymphoplasmacytic cells in the bone marrow.Multiple myelomais the most serious and prevalent plasma cell dyscrasia, with a median age of onset of 60 years. Symptoms result from lytic bone disease...
D57.00 -hyphen D57.819 Sickle-hyphencell disorders Background The terms plasmapheresis (PP) and plasma exchange (PE) are often used interchangeably, but when properly used, denote different procedures. Plasmapheresis refers to a procedure in which the plasma is separated from the blood either by ce...
19,27-30 Furthermore, many of these conditions are also risk factors for VTE and may have initial symptoms or signs similar to PE.29 D-dimer levels are therefore less likely to be useful in patients with suspected VTE and 1 or more of these diagnoses because, for example, increased ...
This panel was developed on the Luminex xMAP (Austin, TX, USA) platform to measure proteins previously reported to be altered in cancer, cardiovascular disease, metabolic disorders and inflammation. RBM also included additional analytes believed to be involved in cell signaling and previously reported...
In classical terms, a plasma cell is a terminally differentiated B lymphocyte, and a myeloma cell is its neoplastically transformed progeny. These are simplistic definitions, for plasma cell disorders (PCDs) are a complex group comprising a diverse spectrum of benign conditions to cancers known as...